.Attribute Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ advanced breast cancer as well as energetic or even stable mind metastases showed regular intracranial task and also systemic efficacy of T-DXd.